The effect of highly purified eicosapentaenoic acid in patients with psoriasis.
Terano
T
T
2nd Department of Internal Medicine, Chiba University School of Medicine, Japan.
Kojima
T
T
Seya
A
A
Tanabe
E
E
Hirai
A
A
Makuta
H
H
Ozawa
A
A
Fujita
T
T
Tamura
Y
Y
Okamoto
S
S
D000328:Adult; D000368:Aged; D001094:Arachidonate 5-Lipoxygenase / Q000097:blood; D000001:Calcimycin / Q000494:pharmacology; D015118:Eicosapentaenoic Acid / Q000627:therapeutic use*; D004890:Erythema; D005260:Female; D005966:Glucuronidase / Q000097:blood; D006801:Humans; D066298:In Vitro Techniques; D007700:Kinetics; D007975:Leukotriene B4 / Q000494:pharmacology; D008297:Male; D008875:Middle Aged; D009504:Neutrophils / Q000187:drug effects* / Q000201:enzymology; D011565:Psoriasis / Q000188:drug therapy* / Q000503:physiopathology; D012867:Skin / Q000503:physiopathology
D007975:Leukotriene B4; D000001:Calcimycin; D015118:Eicosapentaenoic Acid; D001094:Arachidonate 5-Lipoxygenase; D005966:Glucuronidase